GLAND PHARMA LIMITED

August 14, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Appointment of Chief Executive Officer

In compliance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Deepak Sapra, as the new Chief Executive Officer (CEO) of the Company, subject to his acceptance of the Offer made by the Company. Mr. Deepak Sapra will be joining the Company with effect from November 16, 2026.

The details, as required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are given in **Annexure-A**, which is enclosed herewith.

This is for your information and records.

Yours truly,
For Gland Pharma Limited

Pallerlamudi Sampath Kumar
Digitally signed by Pallerlamudi Sampath Kumar
DN: cn=Pallerlamudi Sampath Kumar, c=IN, o=Personal, email=sampath@glandpharma.com
Date: 2026.08.14 08:32:24 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer

Encl: Annexure A

Annexure A

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Details of Mr. Deepak Sapra

SI. No	Particulars	Remarks
1	Reason for change	Appointment of Mr. Deepak Sapra, as the Chief Executive Officer of the Company with effect from November 16, 2026.
2	Date of Change	16.11.2026
3	Brief profile	Mr. Deepak Sapra is a seasoned business leader with 27 years of executive experience, including over 23 years in the pharmaceutical industry. He currently serves as the Chief Executive Officer – API and Services at Dr. Reddy's Laboratories Limited (DRL) and as a Board Member of Aurigene Pharma Services. In his current role, Mr. Deepak Sapra is responsible for the global portfolio strategy and he leads an integrated B2B business spanning generic pharmaceuticals, CDMO services, APIs, collaborations and alliances, public health, and global patient access, with operations and business interests across key markets including the United States, European Union, Japan, Brazil, China, Mexico, the Middle East, emerging markets including Africa. He has a proven track record of driving revenue growth, market expansion and entry, business development, licensing, M&A and portfolio creation across India, the United States, Europe, Latin America, Africa, the Middle East, China, Japan and the broader Asia-Pacific region. His experience encompasses the end-to-end pharmaceutical value chain, including CDMO

		partnerships, generics, APIs, sales and marketing, international business management, business development, supply chain management, R&D, operations, portfolio strategy, public health and access-led partnerships. Prior to his current role, Mr. Deepak served as Chief Executive Officer – Custom Pharmaceutical Services, where he led a global CDMO business serving innovator pharmaceutical companies across the United States, Europe and Japan. During 2011–2015, he held senior leadership positions as Vice President – Global Generics Business Development and Senior Director – Global Generics Portfolio Management. Mr. Deepak Sapra holds a Bachelor's degree in Mechanical Engineering from the Indian Railways Institute of Mechanical and Electrical Engineering, Jamalpur, and a Master's degree in Management from the Indian Institute of Management, Bangalore. He was also a recipient of the Chevening Scholarship at the University of Bradford, UK, and a Fulbright Fellow at Carnegie Mellon University, Pittsburgh, USA.
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable